Stay updated on Venetoclax Combo vs Low Dose Cytarabine in AML Clinical Trial
Sign up to get notified when there's something new on the Venetoclax Combo vs Low Dose Cytarabine in AML Clinical Trial page.

Latest updates to the Venetoclax Combo vs Low Dose Cytarabine in AML Clinical Trial page
- Check6 days agoChange DetectedThe page now shows Revision: v3.5.4, replacing the previous Revision: v3.5.3. This reflects a small update to the documentation or underlying page/versioning system.SummaryDifference0.0%

- Check13 days agoNo Change Detected
- Check20 days agoNo Change Detected
- Check27 days agoChange DetectedThe page’s revision label was updated from **Revision: v3.5.2** to **Revision: v3.5.3**.SummaryDifference0.0%

- Check34 days agoChange DetectedRevision updated from v3.5.0 to v3.5.2.SummaryDifference0.0%

- Check63 days agoChange DetectedAdded Revision: v3.5.0 and removed Revision: v3.4.3 from the page.SummaryDifference0.0%

- Check70 days agoChange DetectedDeleted the citation for Wei AH et al. on risk stratification of low-dose cytarabine and venetoclax in AML (Blood Advances, 2026).SummaryDifference0.0%

- Check77 days agoChange DetectedAdded Revision v3.4.3 and removed Revision v3.4.2.SummaryDifference0.0%

Stay in the know with updates to Venetoclax Combo vs Low Dose Cytarabine in AML Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Venetoclax Combo vs Low Dose Cytarabine in AML Clinical Trial page.